Citations

Clear

1325 citation(s) found for "Mayo, Angela".

Benefits of biologic therapy administered for asthma on co‐existent chronic rhinosinusitis: A real‐world study
Bajpai, Shilpika , Marino, Michael J. , Rank, Matthew A. , Donaldson, Angela M. , O’Brien, Erin K. , Lal, Devyani , Lal, Devyani , O'Brien, Erin K

Mayo Clinic

International Forum of Allergy & Rhinology | February 3, 2021 | Volume: 11 | Issue: 8 | Pages: 1152-1161

10.1002/alr.22774 | PMID 33527730 Get It

BackgroundAsthma and some chronic rhinosinusitis (CRS) subtypes are mediated by similar pathophysiologic mechanisms. The purpose of this study was to evaluate the effects of biologic therapy for asthma on co‐existent CRS in the “real‐world” setting.MethodsA review of electronic health records (2016‐2019) at Mayo Clinic was conducted to identify asthma patients treated with biologics who had co‐existent CRS. Matched‐pair analyses compared pretherapy and posttherapy Lund‐Mackay computed tomography (CT) scores and 22‐item Sino‐Nasal Outcome Test (SNOT‐22) scores. Performance of endoscopic sinus surgery (ESS) after initiating biologics was studied.ResultsWe identified 247 patients who received anti‐asthma biologic therapy and had co‐existent CRS. Of these, 181 patients (73.3%) had CRS with nasal polyposis (CRSwNP) and 66 (26.7%) had CRS without nasal polyposis (CRSsNP). The biologics utilized were omalizumab (51.0%), mepolizumab (46.6%), benralizumab (10.5%), reslizumab (1.6%), and dupilumab (2.4%). Anti‐interleukin‐5 (anti‐IL‐5) intervention was associated with significant improvement in CT scores (CRS overall, CRSwNP subgroup, CRSsNP subgroup) and SNOT‐22 scores (CRS overall, CRSwNP subgroup). Patients on omalizumab had a decrease in CT scores, but not SNOT‐22 scores. ESS was performed in 206 patients (84.1%); 55 (22.3%) underwent surgery post–biologic intervention (anti‐IL‐5: 16.5%; omalizumab 27.8% of patients).ConclusionAnti‐IL‐5 agents were associated with improved CT and SNOT‐22 scores in the overall CRS group and in CRSwNP subgroup; CRSsNP patients showed improved CT scores only. Omalizumab improved CT but not SNOT‐22 scores. ESS was performed in 22% of patients after initiating biologics. These real‐world results may influence future trial designs and clinical applications of biologics for CRS. ©2021 ARSAAOA, LLC.
Effect of Partial Uncinectomy After Balloon Sinuplasty on Maxillary Sinus Irrigant Penetration: A Cadaveric Study
Karataylι-Özgürsoy, Selmin, Gonzalez, Valeria , Olomu, Osarenoma , Donaldson, Angela M. , Martinez-Paredes, Jhon F, Karatayli-Ozgursoy, Selmin, Gonzalez, Valeria V , Martinez‐Paredes, Jhon F.

Mayo Clinic

OTO Open | January 27, 2021 | Volume: 5 | Issue: 1 | Pages: No page available

10.1177/2473974x21989583 | PMID 33598598 Get It

ObjectiveThe uncinate process may play a role in the amount of irrigation penetrance. In this cadaver study, we aimed to investigate if the addition of partial uncinectomy provides better maxillary sinus irrigation penetrance than balloon sinuplasty (BSP) alone.Study DesignCadaveric study.SettingSimulation laboratory at the Mayo Clinic in Florida.MethodsFive fresh‐frozen human cadaveric heads (10 sides) were used to assess maxillary sinus irrigation penetration after 3 interventions performed sequentially: irrigation penetrance with no intervention, irrigation after BSP, and irrigation after BSP and partial removal of the uncinate. Penetrance was recorded with intrasinus endoscopy and scored by 4 blinded observers using a scale from 0 (no irrigation) to 5 (fully irrigated). The diameter of the maxillary ostium was measured before and after BSP. Internal consistency was evaluated with Cronbach’s alpha.ResultsMean ostium size increased from 4.1 to 6.8 mm after BSP (P =. 013). Cronbach’s alpha was 0.93. The median scores of irrigation penetration after no intervention, BSP, and BSP and partial uncinectomy were 2.5, 3, and 4, respectively. We found a significantly higher penetrance following partial uncinectomy plus BSP versus BSP alone (P =. 008). Both interventions had a statistically significant difference in irrigation penetrance as compared with no intervention (P =. 0001).ConclusionMaxillary sinus irrigation penetration increased from baseline after BSP. The addition of a partial uncinectomy to the balloon dilation of the maxillary sinus was associated with a statistically significant increase in irrigation penetrance scores as compared with BSP alone.
Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort
Drosou, Maria Eleni , Vaughan, Lisa E. , Muchtar, Eli , Dingli, David , Fonder, Amie , Gertz, Morie A. , Gonsalves, Wilson I. , Hayman, Suzanne R. , Hobbs, Miriam, Hwa, Yi L. , Kapoor, Prashant , Kourelis, Taxiarchis , Kumar, Shaji , Kyle, Robert A. , Lacy, Martha Q. , Lin, Yi , Lopez, Camden , Lust, John A., Russell, Stephen J. , Sidana, Surbhi , Siddiqui, Mustaqeem , Warsame, Rahma , Dispenzieri, Angela , Fonder, Amie L, Gertz, Morie A , Gonsalves, Wilson , Hwa, Yi L , Kourelis, Taxiarchis , Lopez, Camden L, Rajkumar, S Vincent , Sidana, Surbhi , Sidiqi, M Hasib , Warsame, Rahma , Leung, Nelson , Muchtar, E , Russell, Stephen J , Siddiqui, Mustaqeem A , Lopez, Camden L , Dingli, David , Lin, Yi , Buadi, Francis K. , Dispenzieri, Angela , Go, Ronald S. , Rajkumar, S. Vincent , Sidiqi, M Hasib , Leung, Nelson

Mayo Clinic

American Journal of Hematology | January 15, 2021 | Volume: 96 | Issue: 4 | Pages: 446-454

10.1002/ajh.26092 | PMID 33428787 Get It

AbstractThree sets of criteria (International Society of Amyloidosis [ISA], Palladini and Kastritis) were independently developed for staging, progression and response criteria to predict renal survival in patients with AL amyloidosis. We evaluated these criteria using a cohort of 495 newly diagnosed AL amyloidosis patients with renal involvement using time to event competing risk analysis at baseline, 3, 6 and 12 months after treatment. Only Palladini and Kastritis had a staging system and both predicted a higher risk of end stage renal disease (ESRD) in the stage III vs stage I patients but only the Palladini model was predictive for stage II patients. At 3 months, risk of ESRD was significantly higher for Palladini and ISA renal progression (hazard ratio [HR] 2.8 [95% CI: 1.5–5.3, p = .001] and 2.5 [CI: 1.4–4.6, p = .004, respectively]), but renal response was not significantly protective; conversely, the risk of ESRD was not significantly higher for the Kastritis renal progression, but was significantly protective for the Kastritis renal responders (HR 0.38 [95% CI: 0.17–0.84], p = .017). Both progression and response with ISA, Palladini and Kastritis criteria were predictive of ESRD at 6 months and 12 months. While the Palladini staging criteria at baseline, and the ISA and Palladini criteria for progression at 3 months performed better than the Kastritis criteria at baseline and 3 months post‐treatment, the Kastritis criteria performed better for response 3 months after treatment. All three sets of criteria performed well at and after 6 months post‐treatment. These differences are important when choosing endpoints for clinical trials.
Rapidly Progressive Paraplegia in an 11-Year-Old Girl: A Case of Spinal Cord Infarction and Expected Imaging Findings
Neth, Bryan J. , Hewitt, Angela , Edlund, Wendy , Keating, Gesina F. , Hewitt, Angela L , Edlund, Wendy S , Patterson, Marc C. , Neth, Byran J. , Guérin, J.

Mayo Clinic

Child Neurology Open | December 22, 2020 | Volume: 7 | Issue: No issue available | Pages: 2329048X2098129

10.1177/2329048x20981295 | PMID 33426143 Get It

Rapidly progressive non-traumatic paraplegia in a child is uncommonly encountered in clinical practice, but is an important presentation to consider given the potential for significant morbidity. We present the case of an 11-year-old girl who was found to have hyperacute paraplegia due to spinal cord infarction. We discuss the appropriate workup, differential diagnosis in children and how this relates to adults; and describe the prognosis and current state of management options for spinal cord infarction.
Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first‐line therapy in multiple myeloma
Cook, Joselle , Johnson, Isla McKerrow , Higgins, Alexandra , Sidana, Surbhi , Warsame, Rahma , Gonsalves, Wilson I. , Gertz, Morie A. , Lacy, Martha Q. , Kapoor, Prashant , Kourelis, Taxiarchis , Dingli, David , Fonder, Amie , Hayman, Suzanne R. , Hobbs, Miriam, Hwa, Yi L. , Kyle, Robert A. , Kumar, Shaji , Johnson, Isla, Gonsalves, Wilson , Lacy, Martha, Dispenzieri, Angela , Kourelis, Taxiarchis , Hwa, Yi L , Leung, Nelson , Rajkumar, S Vincent , Gertz, Morie A , Higgins, Alexandra , Sidana, Surbhi , Dingli, David , Cook, Joselle M , Buadi, Francis K. , Dispenzieri, Angela , Leung, Nelson , Go, Ronald S. , Rajkumar, S. Vincent

Mayo Clinic

American Journal of Hematology | December 17, 2020 | Volume: 96 | Issue: 3 | Pages: 330-337

10.1002/ajh.26074 | PMID 33326116 Get It

AbstractInduction therapy for multiple myeloma with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (d) (VRd) was traditionally administered as bortezomib given twice weekly on a 3 week cycle. A modified schedule of weekly bortezomib has been adopted over time to decrease treatment burden for patients and reduce treatment‐emergent neuropathy. This study evaluates the response rates and outcomes with different schedules of bortezomib in VRd administered for first‐line treatment for patients with newly diagnosed MM (NDMM). We retrospectively analyzed patients treated with upfront VRd from June 30th 2008 to December 31st 2018, for variations of bortezomib administration. Five hundred and fifty‐five (555) NDMM patients met inclusion criteria; median age 63 years and 61% men. Bortezomib was administered twice weekly every 21 days in 43%, once weekly every 21 days in 41% and once weekly every 28 days in 16%. Though peripheral sensory neuropathy was more frequent with twice weekly dosing (P = .002), this group achieved shorter time to best response (P = .01). Weekly every 21‐day treatment saw higher VGPR or better rates (P = .02). However, with median follow up time of 37 months (IQR 22–56), we found no difference in PFS or OS among the groups. While small differences in response rates were found among the varying administration schedules of bortezomib administration, there was no significant effect on PFS or OS. Given that VRd remains a first line standard of care option for newly diagnosed MM, in the absence of a large trial comparing bortezomib dosing schedule modifications, these results are helpful in supporting current practices of once weekly administration.
Shared Decision Making in the Era of Telehealth: Implications for Practice and Research
Ozanne, Elissa M. , Cameron, Kenzie A. , Schmidt, Monika M. , Pershing, Mandy L. , Guzmán, Adriana , Sivly, Angela , Cavanaugh, Kerri , Ozanne, Elissa M , Noseworthy, Peter A. , Cavanaugh, Kerri L. , Guzman, Adriana, Fagerlin, Angela

Mayo Clinic

MDM Policy & Practice | December 10, 2020 | Volume: 5 | Issue: 2 | Pages: No page available

10.1177/2381468320976364 | PMID 33344769 Get It

International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease
Rhee, Frits van , Oksenhendler, Éric , Srkalović, Gordan , Voorhees, Peter M. , Lim, Megan S. , Ide, Makoto , Parente, Sophia A. T. , Schey, Stephen, Streetly, Matthew , Wu, David , Brandstadter, Joshua D. , Munshi, Nikhil C. , Bowne, Wilbur B. , Elenitoba‐Johnson, Kojo S.J. , Lechowicz, Mary Jo , Chandrakasan, Shanmuganathan , Pierson, Sheila K. , Greenway, Amy D, Yoshizaki, Kazuyuki , Chadburn, Amy , van Rhee, Frits , Ide, Makoto , Lim, Megan S , Chandrakasan, Shanmuganathan , Dispenzieri, Angela , Wong, Raymond , Maillard, Ivan P. , Fosså, Alexander , Nasta, Sunita , Kurzrock, Razelle , Uldrick, Thomas S. , Casper, Corey , Fajgenbaum, David C.

Mayo Clinic

Blood Advances | December 9, 2020 | Volume: 4 | Issue: 23 | Pages: 6039-6050

10.1182/bloodadvances.2020003334 | PMID 33284946 Get It

Abstract Castleman disease (CD) includes a group of rare and heterogeneous disorders with characteristic lymph node histopathological abnormalities. CD can occur in a single lymph node station, which is referred to as unicentric CD (UCD). CD can also involve multicentric lymphadenopathy and inflammatory symptoms (multicentric CD [MCD]). MCD includes human herpesvirus-8 (HHV-8)–associated MCD, POEMS-associated MCD, and HHV-8−/idiopathic MCD (iMCD). The first-ever diagnostic and treatment guidelines were recently developed for iMCD by an international expert consortium convened by the Castleman Disease Collaborative Network (CDCN). The focus of this report is to establish similar guidelines for the management of UCD. To this purpose, an international working group of 42 experts from 10 countries was convened to establish consensus recommendations based on review of treatment in published cases of UCD, the CDCN ACCELERATE registry, and expert opinion. Complete surgical resection is often curative and is therefore the preferred first-line therapy, if possible. The management of unresectable UCD is more challenging. Existing evidence supports that asymptomatic unresectable UCD may be observed. The anti–interleukin-6 monoclonal antibody siltuximab should be considered for unresectable UCD patients with an inflammatory syndrome. Unresectable UCD that is symptomatic as a result of compression of vital neighboring structures may be rendered amenable to resection by medical therapy (eg, rituximab, steroids), radiotherapy, or embolization. Further research is needed in UCD patients with persisting constitutional symptoms despite complete excision and normal laboratory markers. We hope that these guidelines will improve outcomes in UCD and help treating physicians decide the best therapeutic approach for their patients.
Investigating gene expression changes underlying selective hippocampal vulnerability in Alzheimer’s disease using a translational neuropathology approach
Crist, Angela M. , Hinkle, Kelly M., Wang, Xue , Lesser, Elizabeth R. , Azu, Nkem O. , Frankenhauser, Isabelle , Liesinger, Amanda M., Serie, Daniel, DeTure, Michael , Cook, Casey , Petrucelli, Leonard , Petersen, Ronald C. , Duara, Ranjan , Graff‐Radford, Neill R. , Allen, Mariet , Carrasquillo, Minerva M. , Ertekin‐Taner, Nilüfer , Asmann, Yan W. , Moloney, Christina M. , Labuzan, Sydney A. , Matchett, Billie J. , Duara, Ranjan , Carrasquillo, Minerva M. , Li, Hu, Ross, Owen A. , Dickson, Dennis W. , Carter, Rickey E. , Murray, Melissa E.

Mayo Clinic

Alzheimer's & Dementia | December 7, 2020 | Volume: 16 | Issue: S2 | Pages: No page available

10.1002/alz.041199 Get It

AbstractBackgroundUsing an objective mathematical algorithm to assess corticolimbic involvement of neurofibrillary tangle pathology, we identified three AD subtypes: hippocampal sparing (HpSp) AD, typical AD, and limbic predominant AD. Typical AD brains were representative of the expected patterns of hippocampal and cortical involvement as outlined by Braak tangle stage. In contrast, we discovered an extreme phenotype that exists outside of the Braakian‐concept of neurofibrillary tangle patterns. Hippocampal sparing AD cases demonstrate unexpected sparing of the hippocampus relative to severely involved association cortices and limbic predominant AD cases demonstrate inundation of the hippocampus relative to mildly involved association cortices. Using these AD subtypes, our objective was to leverage our understanding of disease spectrum to uncover transcriptomic changes that underlie selective vulnerability of the hippocampus in AD.MethodWe performed RNA‐sequencing in 40 neuropathologically diagnosed AD cases (10 HpSp, 20 Typical and 10 Limbic) and 15 controls to uncover gene expression changes associated with phenotype differences allowing us to prioritize 44 genes for further exploration. Validation with NanoString and quantification with digital pathology were performed in an expanded cohort of 158 AD cases (36 HpSp, 79 Typical and 35 Limbic) and 32 controls. We quantified digital pathology measures of early tangle pathology (CP13), mature tangle pathology (Ab39), amyloid‐β (33.1.1). In addition, we measured cellular markers for microglia (CD68), endothelia (CD34), and astroglia (GFAP). Deep learning based prediction models were employed, which nominated the SLC38A2 gene as a predictor of AD.ResultThe SLC38A2 gene was originally prioritized in our RNA‐sequencing data based upon differential expression between controls and typical AD. We observed upregulation of SLC38A2 in all AD subtypes. RNA‐seq gene expression measures validated well with NanoString for SLC38A2 (R=0.97, p<0.001). Regression analysis identified early tangle (p=0.011) and late tangle measures (p=0.026) as significant predictors of gene expression, but not amyloid measures (p=0.74). Microgliosis approached significance (p=0.052), but with no contribution from endothelial cell burden (p=0.17) or astrogliosis (p=0.58). Age approached significance (p=0.06), but not sex (p=0.88) or APOE‐ε4 status (p=0.10).ConclusionOur data supports consideration of intra‐disease divergence with regard to case stratification and may reveal genes previously masked by heterogeneity of cohorts.
Non-Cardiac Biopsy Sites with High Frequency of Transthyretin Amyloidosis
Dasari, Surendra , Mansour, Shareef , Muppa, Prasuna, Kurtin, Paul J. , Theis, Jason D. , Vrana, Julie A., Grogan, Martha , Kourelis, Taxiarchis , McPhail, Ellen Darcy , Dispenzieri, Angela , Gertz, Morie A.

Mayo Clinic

ESC Heart Failure | December 5, 2020 | Volume: 8 | Issue: 1 | Pages: 750-755

10.1002/ehf2.13130 | PMID 33277823 Get It

Abstract Aims Cardiac scintigraphy, a non-invasive technique for diagnosing ATTR cardiac amyloidosis, lacks specificity in patients with concomitant monoclonal gammopathy (up to 40% of cases). For these patients, amyloid type is often established by endomyocardial biopsy (EMB), which has clinical risk. This study aimed to investigate the frequency of ATTR in amyloid-positive tendon/synovium, urinary bladder, and prostate biopsies, sites for which prior biopsy specimens might exist for patients suspected of having cardiac amyloidosis, and, when available, determine the amyloid type concordance rate with other anatomic sites and provide clinical data regarding subsequent development of cardiac amyloidosis. Methods and results We queried our reference laboratory database of 19,298 amyloid specimens from myriad anatomic sites typed by mass spectrometry-based proteomics (LC-MS/MS) to investigate the frequency of ATTR amyloid in tendon/synovium, urinary bladder, and prostate. The amyloid type was ATTR in 104/138 (75.4%) tendon/synovium, 173/453 (38.0%) urinary bladder, and 27/81 (33.3%) prostate samples. Of 62 patients with available clinical data, 12 (19%) had bona fide ATTR cardiac amyloidosis prior to/concomitant with the non-cardiac site biopsy. Of the remaining 14 with follow-up, 8 developed bona fide and 2 probable cardiac amyloidosis; at last follow-up 4 had no evidence of cardiac amyloidosis. Fourteen of 16 patients (87.5%) for whom we typed both non-cardiac and cardiac sites had concordant amyloid types. There were 2 discordant cases (prostate = ASem1/heart = AL and urinary bladder = AL/heart = ATTR); only the latter is potentially clinically consequential. Conclusions In patients suspected of having cardiac amyloidosis based on cardiac scintigraphy, LC-MS/MS typing of Congophilic deposits in pre-existing biopsy specimens from non-cardiac sites may help establish the cardiac amyloid type, obviating the need for EMB. However, if the amyloid type identified in the non-cardiac site is not in keeping with other clinical features, then EMB for typing the cardiac amyloid might be indicated.